交易季度统计报告
Financing Quarterly During Q2, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.7bn.
报告摘要
Financing Quarterly During Q2, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.7bn.
报告信息
- 文件全名
- 《交易季度统计报告-13页.pdf》
- 适合读者
- 核心数据
- category made up the greatest proportion of both the aggregate Q2 financing dollars (26%) and deal volume (33%)
- There were 67 biopharmas together raising $4.6bn through 47 early-stage rounds totaling $2.9bn (16% of the
- quarter’s dollars) and 20 late-stage rounds totaling $1.7bn (10% of the Q2 dollars). Early-stage rounds had an
- Debt offerings represented the second-highest share of deal dollars (21%), with 18 deals bringing in an aggregate
- 核心议题
常见问题
《交易季度统计报告》主要包含哪些内容?
Financing Quarterly During Q2, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.7bn.核心数据:category made up the greatest proportion of both the aggregate Q2 financing dollars (26%) and deal volume (33%);There were 67 biopharmas together raising $4.6bn through 47 early-stage rounds totaling $2.9bn (16% of the;quarter’s dollars) and 20 late-stage rounds totaling $1.7bn (10% of the Q2 dollars). Early-stage rounds had an。
这份报告覆盖哪一年、篇幅多大?
覆盖 2025 年,全文约 13。
这份报告是免费的吗?如何获取?
本报告免费查阅,登录资料宝后即可在线获取完整内容。
这份报告适合哪些读者?
适合投资人、行业研究员等读者参考。
报告涉及哪些关键议题?
重点分析了IPO等议题。
继续阅读
查看全部 →